ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in San Francisco, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Renal Cell Carcinoma
Cutaneous Malignant Melanoma
Lung Cancer

Melanoma trials near San Francisco, CA, USA:

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

This phase II trial studies how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be....

Enrolling
Melanoma Stage IV
Melanoma Stage III
Drug: Binimetinib
Drug: Imatinib

Phase 2

University of California San Francisco (UCSF)
University of California San Francisco (UCSF)

San Francisco, California, United States and 1 other location

Status recently updated

This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma...

Begins enrollment this month
Enrolling
Uveal Melanoma
Procedure: Primary Local Therapy
Drug: Darovasertib

Phase 3

Ideaya Biosciences

Palo Alto, California, United States and 59 other locations

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...

Enrolling
Uveal Melanoma
Drug: Darovasertib

Phase 2

Ideaya Biosciences

Palo Alto, California, United States and 24 other locations

The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question ...

Enrolling
Melanoma Stage IIIB-IV
Melanoma (Skin Cancer)
Biological: Immunotherapy (ipilimumab and nivolumab)
Biological: Immunotherapy (Pembrolizumab)

Phase 2, Phase 3

Linnaeus Therapeutics

San Francisco, California, United States and 6 other locations

ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma...

Enrolling
Advanced Melanoma
Drug: Fianlimab
Drug: Cemiplimab

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Stanford, California, United States and 9 other locations

alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...

Enrolling
Melanoma
Unresectable Melanoma
Biological: Pembrolizumab with Optional Crossover Period
Biological: Lifileucel plus Pembrolizumab

Phase 3

Iovance Biotherapeutics

San Francisco, California, United States and 71 other locations

and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + tram...

Enrolling
Advanced or Metastatic NRAS-mutant Melanoma
Drug: Trametinib
Drug: Naporafenib

Phase 3

Erasca

San Francisco, California, United States and 58 other locations

The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the com...

Enrolling
Melanoma
Drug: fianlimab
Drug: cemiplimab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

San Francisco, California, United States and 100 other locations

efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...

Enrolling
Ocular Melanoma
Choroidal Melanoma
Device: Suprachoroidal Microinjector
Drug: Bel-sar

Phase 3

Aura Biosciences
Aura Biosciences

Palo Alto, California, United States and 64 other locations

To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investig...

Active, not recruiting
Uveal Melanoma
Biological: IMCgp100
Biological: Pembrolizumab

Phase 2

Immunocore
Immunocore

San Francisco, California, United States and 56 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems